InsitroTranslation site

Insitro is an innovative company with a significant presence in the field of drug discovery and development.

Company Overview

• Established: Insitro was founded in 2018 and is based in the United States.
• creator: Founded by Prof. Daphne Koller of Stanford University.
• Company size: According to IT Orange (ITOrange.com), Insitro is between 100-300 people.
• Company Positioning: Insitro is a cutting-edge biotechnology company focused on revolutionizing the drug discovery and development process using artificial intelligence (AI) and machine learning technologies.

Core business and technology

• drug development: Insitro is dedicated to accelerating the process of new drug development and improving the success rate of drugs by combining advanced computational methods and biological experiments. Its core technology is a bioinformatics approach based on artificial intelligence and machine learning algorithms, which utilizes big data and advanced computational models to analyze biological data such as gene expression, protein interactions, and disease-related genetic variation.
• innovative treatment: The company has a special focus on the development of new therapies for difficult-to-treat diseases such as non-alcoholic steatohepatitis (NASH). Through AI technology, Insitro is able to screen and validate potential drug candidates more quickly, resulting in shorter drug development cycles and lower development costs.

Financing

Insitro has achieved significant results in terms of financing, which provides strong support for its continued innovation in the field of drug discovery and development. Insitro has completed several rounds of financing, according to Eye on the Sky:

• Series A financing: In May 2018, Insitro closed a $100 million Series A round of funding from Third Rock Ventures, ARCH Venture Partners, T. Rowe Price, Two Sigma Ventures, Alexandria Venture Investments, Google Ventures, Bezos Expeditions, Foresite Capital, Verily, and Andreessen Horowitz.
• Series B Financing: In May 2020, Insitro secured another $143 million Series B round of financing, with investors continuing to ramp up, including Andreessen Horowitz, WuXi AppTec, Third Rock Ventures, ARCH Venture Partners, T. Rowe Price, Two Sigma Ventures, Google Ventures, Bezos Expeditions, Foresite Capital and HOF Capital.
• Series C Financing: In March 2021, Insitro closed a $400 million Series C financing led by Canadian pension fund CPPIB, with ARCH Venture Partners, Google Ventures, Andreessen Horowitz, T. Rowe Price, Two Sigma Ventures, Third Rock Ventures, Temasek Temasek, SoftBank Vision Fund and HOF Capital.

Honors and Recognition

Insitro has been widely recognized and praised by the industry for its excellence in AI drug discovery and development:

• Forbes AI 50 listInsitro has been named to Forbes Magazine's "AI 50" list, which recognizes the world's most promising artificial intelligence companies, in multiple years.2024, Insitro was ranked 23rd on the list with $643 million raised.
• Hurun Global Unicorn List: Insitro has also been named to the Hurun Global Unicorn List published by the Hurun Research Institute, demonstrating its strong potential and value in the biotechnology and pharmaceutical sectors.

future outlook

With the continuous development of AI technology and the expansion of application fields, Insitro will continue to play an important role in the field of drug research and development. The company will continue to increase its investment in technology research and development and talent training to promote the deep integration of AI and biotechnology and make greater contributions to human health. At the same time, Insitro will also actively seek to establish cooperative relationships with partners around the world to jointly promote innovation and development in the field of drug discovery and development.